Login / Signup

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).

Hyun Ae JungKeon Uk ParkSang Hee ChoJinyeong LimKeun-Wook LeeMin Hee HongTak YunHo Jung AnWoong-Yang ParkSergio PereiraChan-Young OckBhumsuk Keam
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Nivolumab plus gemcitabine showed promising efficacy with favorable toxicity profiles in patients with advanced NPC in whom platinum-based combination chemotherapy failed.
Keyphrases
  • locally advanced
  • phase ii study
  • squamous cell carcinoma
  • rectal cancer
  • radiation therapy
  • small cell lung cancer
  • oxidative stress
  • open label
  • clinical trial
  • randomized controlled trial
  • study protocol